Drugs / IGF-1R/AS ODN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01550523 | Feb 2012 → Jun 2013 | malignant glioma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGF-1R/AS ODN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01550523 ↗ |
| Action | Inhibit | “designed to shut down a targeted surface receptor protein” NCT01550523 ↗ |
| Modality | Antisense oligonucleotide | “an investigational new drug (an antisense molecule)” NCT01550523 ↗ |
| Target | IGF1R | “Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide” NCT01550523 ↗ |